Gastroenterology & Hepatology
Does switching to subcutaneous vedolizumab affect remission rates for inflammatory bowel disease?
Background Vedolizumab is an effective treatment option for inflammatory bowel diseases (IBD), usually administered intr...
23 May 2024
